Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin
Authors:
Open Access
- 10 July 2023
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 16 (1) , 503-509
Abstract
We encountered a case in which the general condition of a patient receiving cabazitaxel worsened with concomitant use of clarithromycin. Cabazitaxel is metabolized mainly by CYP3A4, and the frequency of adverse events is known to increase with increasing exposure. Although these drugs are not often quantified in daily practice, we quantified them because we considered it possible that the blood concentration of cabazitaxel had increased due to CYP3A4 inhibition of clarithromycin and that cabazitaxel-related adverse events had occurred. However, the concentration of cabazitaxel was not increased and we attributed the patient’s deterioration to decreased tolerability of cabazitaxel. At least at a trough concentration of 70 ng/mL, which is the trough concentration when a normal dose of clarithromycin is administered, clarithromycin does not appear to have a significant effect on the blood concentration of cabazitaxel. This case suggests that the administration of the normal dose of clarithromycin might be relatively safe in patients receiving cabazitaxel.Keywords
This publication has 15 references indexed in Scilit:
- A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumorsAnti-Cancer Drugs, 2015
- Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxelCancer Chemotherapy and Pharmacology, 2014
- Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancerCancer Chemotherapy and Pharmacology, 2014
- Retrospective Analysis of Severe Neutropenia in Patients Receiving Concomitant Administration of Docetaxel and ClarithromycinChemotherapy, 2013
- Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycinEuropean Journal of Clinical Pharmacology, 2012
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of??Standard DrugsClinical Pharmacokinetics, 2007
- Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelClinical Pharmacology & Therapeutics, 2004
- Docetaxel and ketoconazole in advanced hormone‐refractory prostate carcinomaCancer, 2003
- Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral dosesAntimicrobial Agents and Chemotherapy, 1992